



## Asensus Surgical to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

May 20, 2021

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 20, 2021-- [Asensus Surgical](#), Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer MedTech, Tools & Diagnostics Summit taking place May 26, 2021.

The Company's presentation will be available on-demand beginning May 26, 2021 at 8:00 am ET.

The on-demand conference presentation will be available online on the investor relations page of the Company's website at <https://ir.asensus.com/events-and-presentations>. Replays of the webcasts will be archived on the website for approximately 90 days.

### About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the clinical intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: [www.senhance.com](http://www.senhance.com). Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: [www.senhance.com/indications](http://www.senhance.com/indications). For more information, visit [www.asensus.com](http://www.asensus.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210520005191/en/): <https://www.businesswire.com/news/home/20210520005191/en/>

### INVESTOR CONTACT:

Mark Klausner or Mike Vallie, 443-213-0499

[invest@asensus.com](mailto:invest@asensus.com)

or

### MEDIA CONTACT:

Kristin Schaeffer

CG Life

[kschaeffer@cglife.com](mailto:kschaeffer@cglife.com)

Source: Asensus Surgical, Inc.